John Heymach, MD, PhD
Articles
Experts Share Top Takeaways From AACR Annual Meeting 2025
During interviews at the American Association for Cancer Research (AACR) Annual Meeting 2025, experts shared key insights from this year's conference.
Zongertinib Shows Benefit Across Subgroups in HER2-Mutated NSCLC: John Heymach, MD, PhD
Zongertinib shows promise for treating HER2-mutant non–small cell lung cancer (NSCLC), with significant activity against brain metastases and low interstitial lung disease risk, explains John Heymach, MD, PhD.
Zongertinib Shows Durable Responses in Previously Treated HER2-Mutated NSCLC: John Heymach, MD, PhD
John Heymach, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses the promising results of zongertinib for HER2-mutated non–small cell lung cancer, showcasing high response rates and improved patient quality of life.
